Table 2.
Other upcoming and ongoing trials of agents in malignant pleural mesothelioma.
| Class | Agent | Phase | ClinicalTrials.gov identifier |
|---|---|---|---|
| Chemotherapy | Maintenance pemetrexed | II | NCT01085630 |
| Antibody against CTLA4 | Tremelimumab | IIb | NCT01843374 |
| Antibody against PD-L1 | Pembrolizumab | II | NCT02399371 |
| Antibody against PD-1 | Nivolumab | II | NCT02497508 |
| MET tyrosine kinase inhibitor | Tivantinib | I | NCT02049060 |
| MET tyrosine kinase inhibitor | Tivantinib | II | NCT01861301 |
| Monoclonal antibody against mesothelin | Amatuximab | II | NCT02357147 |
| Anti-mesothelin antibody-drug conjugate | BAY94-9343 | I | NCT01439152 |
| Pan-VEGF receptor tyrosine kinase inhibitor | Cediranib | I/II | NCT01064648 |
| FAK inhibitor | Defactinib | II | NCT02004028 |
| HSP90 inhibitor | Ganetespid | I/II | NCT01590160 |
CTLA4, cytotoxic T lymphocyte antigen-4; FAK, focal adhesion kinase; HSP90, heat shock protein 90; PD-1, programmed death 1; PD-L1, programmed death 1 ligand; VEGF, vascular endothelial growth factor.